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inTrOducTiOn
Immunofluorescence is a powerful technique that utilizes 
fluorescent-labeled antibodies to detect specific target 
antigens. It is used widely in both scientific research and 
clinical laboratories. This article presents key concepts in 
the use of antibodies in immunofluorescence and their 
application in the diagnosis of dermatologic diseases.
anTiBOdies
An antibody is a protein complex produced by B cells that 
initiates an immune response against a target antigen. The 
basic organization of an antibody includes two function-
al domains that, together, resemble the letter Y (Figure 1, 
left). The Fab (fragment having the antigen binding site) 
domain makes up the arms of the Y, and at the end of each 
arm is a variable region responsible for antigen binding, 
called the antigen-binding site. The Fc (fragment that crys-
tallizes) domain comprises the tail of the Y, which effec-
tor cells, immune proteins, and other antibodies recognize 
primarily. This unique structure allows direct detection 
of antigens in the skin using a single fluorophore-labeled 
antibody or indirect detection through binding of a fluo-
rophore-labeled secondary antibody raised against the Fc 
domain of an unlabeled primary antibody (Figure 1, right). 
Because the Fc domain is conserved within a species, the 
labeled secondary antibody can be used to detect any pri-
mary antibody raised from a single species. This system is 
versatile and cost-effective because few labeled antibodies 
are required to detect many possible primary antibodies. 
For more information about laboratory procedures using 
antibodies, see Harlow and Lane (1999).
In certain bullous diseases, connective-tissue diseases, 
and vasculitides, patients produce antibodies against an 
antigen in their own skin or blood vessels. Detection and 
characterization of the autoantibody–antigen complexes 
is accomplished by laboratory analysis of a skin biopsy 
and (possibly) a blood sample. Clinically, it is important 
to collect the biopsy from the appropriate location for 
the type of autoimmune disease under consideration. 
Because immune deposits are degraded in inflamed 
or blistered skin, bullous diseases require biopsy of 
normal-appearing skin immediately adjacent to a lesion, 
whereas connective tissue diseases and vasculitides can 
be evaluated by biopsy of the skin lesion itself. The biopsy 
can be stored temporarily in Michel’s transport medium 
(3.12 M ammonium sulfate, 5 mM N-ethylmaleimide, 
5 mM magnesium sulfate heptahydrate, and 25 mM 
potassium citrate, pH 7.0) (Michel et al., 1972). The near-
saturating concentration of ammonium sulfate preserves 
autoantibody–antigen complexes of the specimen for 
days by precipitating the proteins, which prevents them 
from diffusing away from their original location in the 
tissue. However, the transport medium is not a fixative, so 
the integrity of cellular membranes will be lost over time 
(Vaughn Jones et al., 1995).
WHAT IMMUNOFLUORESCENCE DOES
•  Immunofluorescence is a microscope-based 
technique used clinically to diagnose certain 
cutaneous diseases by detection of autoantibody–
antigen complexes.
•  Techniques including direct immunofluorescence, 
indirect immunofluorescence, and salt-split skin 
are utilized depending on the clinical scenario.
•  Direct immunofluorescence is performed on 
patients’ skin using fluorophore-labeled antibodies 
that directly bind to the pathogenic autoantibody–
antigen complexes in the skin.
•  Indirect immunofluorescence techniques are 
used in dermatology primarily to detect circulating 
pathogenic autoantibodies.
LIMITATIONS
•  Fluorescence signals depend on the quality and 
concentration of the antibody, proper handling of 
the specimen, and detection with the appropriate 
secondary antibodies.
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target, after which a fluorophore-labeled second antibody 
(directed against the Fc portion of the primary antibody) 
is used to detect the first antibody. This technique is more 
complicated and time consuming than direct immunofluo-
rescence (because it requires a second incubation period); 
however, it is more sensitive because more than one sec-
ondary antibody can bind to each primary antibody, which 
amplifies the fluor escence signal. A variation of indirect 
immunofluorescence testing is used to detect circulating 
autoantibodies in immunobullous diseases. In this situation, 
the primary antibody is the suspected autoantibody in the 
patient serum. The serum is incubated with thin sections 
of normal human skin or other animal tissues, which are 
known to consistently and sensitively bind the antibody of 
interest. Monkey esophagus, for example, is an excellent 
substrate for detecting antidesmoglein antibodies. When 
the test is positive, autoantibodies in the serum bind to the 
target antigen in the tissue sample; the second, fluorophore-
labeled antibody then binds to the Fc portion of the auto-
antibody, allowing it to be visualized with the fluorescence 
microscope. The fluorescence pattern created by the cir-
culating autoantibodies demonstrates the same pattern as 
would a perilesional skin biopsy with DIF.
salT-spliT sKin
Certain diseases cannot be distinguished using routine DIF 
techniques. Bullous pemphigoid (BP; with autoantibod-
ies against BP180 and BP230 antigens) and epidermolysis 
direcT immunOFluOrescence (diF)
DIF uses fluorescent-tagged antibodies to bind directly to the 
target antigen in the skin. In autoimmune bullous diseases, 
the target antigen is the autoantibody or complement that 
causes the blister. Once the tissue is received in the labo-
ratory, it is washed, rapidly frozen, and cut into 5- to 6-μm 
sections that are placed on glass slides. The slides are incu-
bated with the fluorescent-tagged antibodies directed against 
the target antigen. Typically, a panel of antibodies directed 
against different antibody isotypes (IgA, IgG, IgM), as well 
as complement, is used. A drop of each fluorescent-labeled 
antibody is placed on a separate tissue section as well as 
appropriate positive and negative controls. The working con-
centration of each antibody is previously titrated to obtain 
the highest signal-to-background ratio. The slides are incu-
bated for 30 minutes at room temperature in a dark, humidi-
fied chamber. The antibody is then drained, the slides are 
washed, and the labeled tissue sections are mounted and 
viewed with a fluorescence microscope. Diagnosis is based 
on the binding pattern (for example, intercellular, linear at 
dermal–epidermal junction), as well as the isotype (for exam-
ple, IgG, IgA) of the antibody detected.
DIF techniques can also be used to detect nonantibody 
targets in the skin, such as infectious organisms. In this case, 
a fluorophore-labeled primary antibody directed against the 
suspected antigen is used to detect the presence or absence 
of the organism. This technique is rapid and quite specif-
ic, but, owing to the limited number of antibodies that can 
bind to the specific target, it may be less sensitive than other 
microbiologic techniques.
indirecT immunOFluOrescence
Indirect immunofluorescence utilizes a two-step tech-
nique, in which a primary, unlabeled antibody binds to the 
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Figure 1. antibody structure and interactions. (Left) A cartoon of an IgG 
antibody. Each oval represents a 110-amino-acid domain. The dark blue 
ovals together represent a heavy-chain polypeptide, the magenta ovals 
represent a light-chain polypeptide, and the yellow rectangles represent 
disulfide bonds between polypeptides. (Right) An antigen (purple) and a 
fluorophore-conjugated secondary antibody demonstrate the binding events 
between antigen recognition and the fluorescent signal.
Figure 2. Time course of desmosome disassembly in response to 
pemphigus vulgaris (pV) igG. Keratinocytes (KCs) were exposed to PV IgG 
at 4°C for 20 minutes and subsequently shifted to 37°C for 1, 3, 6 and 24 
hours. The localization of human IgG and desmoplakin (DP) was monitored 
by immunofluorescence microscopy. In cells incubated at 4°C (a−c), PV 
IgG labels cell borders and desmoplakin staining is predominantly in 
punctate linear patterns at cell-cell junctions. After 1 hour of treatment, 
with PV IgG (d−f), the PV IgG-desmoglein-3 (Dsg3) molecules accumulate 
in a puncta that are distal to cell-cell borders, whereas desmoplakin  
(e) staining is unchanged. KCs treated with PV IgG for 3 and 6 hours exhibit 
a rearrangement of desmoplakin into linear arrays emanating from cell 
borders, which contain both Dsg3 and desmoplakin. Following treatment 
with PV IgG for 24 hours (m−o) both Dsg3 and desmoplakin are noticeably 
mislocalized and/or absent from cell-cell junctions. Bar = 10 μm. Reprinted 
from Jennings et al. (2011).
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bullosa acquisita (with autoantibodies against collagen VII) 
both create a linear band of IgG and complement at the der-
mal–epidermal junction. Splitting the skin prior to evaluation 
allows these target antigens to be more accurately localized. 
The skin is incubated in 1 M sodium chloride, which splits 
the skin at the level of the lamina lucida. Collagen VII 
immune complexes are retained on the dermal side and 
BP180 immune complexes on the epidermal side of the sam-
ple, allowing discrimination between the two diseases.
limiTaTiOns
A number of factors can affect the quality of a fluorescence 
image. The quality and concentration of the labeled 
antibody are important to achieve a high signal-to-
background ratio. Too much nonspecific antibody binding 
from either a poor-quality antibody or a high concentration 
may not allow accurate localization of immune complexes. 
Alternatively, a dilute antibody may not provide sufficient 
signal. Proper handling of the biopsy specimen, with storage 
in Michel’s transfer medium or flash freezing, is important 
to retain the location and antigenicity of the immune 
complexes. Finally, the signal from fluorescent probes is 
lost over time with exposure to light (a phenomenon called 
bleaching). Therefore, it is important to keep samples in the 
dark when not in use, use only as much light as necessary 
from the microscope, and use an antifade agent in the 
mounting medium, such as p-phenylenediamine (for a 
review of the principles of fluorescence microscopy, see 
Lichtman and Conchello, 2005).
Further limitations of immunofluorescence relate to how 
dermatologic diseases are diagnosed. Currently, bullous 
diseases are diagnosed by immunofluorescence based on 
the location of the autoimmune complexes, the presence 
of inflammatory infiltrates, the class of the autoantibody, 
and the morphology of the immune complexes (e.g., 
continuous, linear, granular) (for a complete review, see 
Mutasim and Adams, 2001). Because immunofluorescence 
is the gold standard for diagnosis of bullous diseases, it 
is difficult to assess the sensitivity and specificity of the 
technique. Also, if a limited set of antibodies is used in 
the clinical laboratory, diseases with an untested class of 
antibody, such as those mediated by IgA, may be missed. 
This scenario is circumvented by testing all samples with a 
standardized panel of antibodies directed against human 
IgG, IgM, and IgA and complement C3. The application 
of enzyme-linked immunosorbent assay, a technique in 
which a recombinant antigen is detected with a primary 
and enzyme-linked secondary antibody, to diagnose 
autoimmune bullous diseases may have its use in certain 
clinical settings (Amagai et al., 1999).
immunOFluOrescence in BullOus diseases
Jennings et al. used immunofluorescence techniques 
to study the spatial and temporal changes of the 
desmosomal protein desmoglein 3 (Dsg3) induced 
by anti-Dsg3 antibodies, which are associated with 
pemphigus vulgaris (PV) (Jennings et al., 2011). As shown 
in the top panels of Figure 2, PV IgG first binds Dsg3 on 
the surface of keratinocytes, consistent with its in vivo 
location in desmosomes. Over time, some Dsg3 moves 
to intracellular punctate structures, as shown at the 1- 
and 3-hour time points, suggesting that the autoantibody 
induces Dsg3 endocytosis. By utilizing fluorophores 
with different emission spectra, the authors were also 
able to follow the signal from desmoplakin, a second 
desmosomal protein. The center row in Figure 2 shows 
that desmoplakin remains mostly at the cell surface during 
Dsg3 endocytosis and rearranges into linear arrays prior to 
eventual degradation. The bottom row of Figure 2 shows 
merged images of the fluorescent antibody signals. As in 
the top row, green areas represent the anti-PV IgG signal, 
red areas the antidesmoplakin antibody signal, and yellow 
areas the overlay of the green plus red signals. Together, 
the images suggest a progressive loss of nondesmosomal 
Dsg3 from the plasma membrane via endocytosis, 
followed by internalization of desmosomal proteins and 
eventual degradation.
Patients with paraneoplastic pemphigus also express 
anti-Dsg3 antibodies. In a study by Saleh et al. (2012), 
phage display was used to isolate monoclonal antibodies 
against Dsg3 from a patient with paraneoplastic 
pemphigus. By incubating them with normal human skin 
and then detecting the immune complexes with a labeled 
secondary antibody, the authors showed that three of the 
antibodies generated the expected pattern in the basal 
epidermis (Figure 3a–c). A fourth autoantibody bound 
recombinant Dsg3 in an enzyme-linked immunosorbent 
assay, but did not stain the basal epidermis, indicating 
that recombinant proteins and fresh tissue may present 
altered epitopes (Figure 3d). As well, it was previously 
shown that anti-Dsg3 antibodies bind calcium-sensitive 
epitopes, so the authors reveal evidence that the staining 
here is also calcium-dependent in Figure 3f because it 
can be abrogated by preincubation of the skin with the 
Figure 3. immunological analysis of anti-desmoglein-3 (dsg3) mabs 
isolated from the paraneoplastic pemphigus (pnp) patient. Indirect 
immunofluorescence of anti-Dsg3 single-chain variable fragment (scFv) 
clones in human skin. (a) PNP-A1, (b) PNP-B1, and (c) PNP-C1 showed 
cell surface staining of the keratinocytes, whereas clone (d) PNP-D1, 
was negative. (e) An scFv isolated from a pemphigus vulgaris (PV) patient 
(D31)2/28 was used as a positive control. (f) Pretreatment of human 
skin cryosections with EDTA prevented the cell binding of PNP-C1 to 
keratinocytes. Bar = 100 μm. Reprinted from Saleh et al. (2012).
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metal chelator EDTA. Figure 3e shows the staining pattern 
generated by incubating normal skin with the serum from a 
patient with PV as a positive control.
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SUPPLEMENTARY MATERIAL
Answers and a PowerPoint slide presentation appropriate for journal club 
or other teaching exercises are available at http://dx.doi.org/10.1038/
jid.2012.455.
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QUESTIONS
1. What is the purpose of Michel’s solution?
A. Fix the tissue before detection.
B.  Cross-link cellular components to retain the 
integrity of cellular structures.
C.  Disrupt plasma membranes to give antibodies 
access to their target antigens.
D.  Precipitate the immune complexes to preserve 
antigenicity.
2.  How many additional antibodies are required to 
detect autoimmune complexes?
A. 1.
B. 2.
C. 3.
D. 4.
3.  Which of the following techniques is more sensitive 
than immunofluorescence for the diagnosis of some 
autoimmune bullous diseases?
A. Light microscopy.
B. ELISA.
C. Dermatoscope.
D. Western blot.
Answers to the questions and an opportunity to comment on the 
article are available on our blog: http://blogs.nature.com/jid_jottings/.
